FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy

The Food and Drug Administration (FDA) approved Shionogi’s Xocova as the first oral post-exposure therapy for the prevention of Covid-19. This approval marks a significant advancement in Covid-19 prevention treatments.

The FDA’s decision signifies a new approach to managing Covid-19, providing an oral option for individuals seeking to prevent the virus after potential exposure. Xocova’s approval introduces a convenient method for post-exposure prophylaxis, potentially reducing the severity and spread of the disease.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI